Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

1. Acupuncture modulates the microbiota-gut-brain axis to treat irritable bowel syndrome: a mechanistic exploration.Frontiers in neuroscience · 2026
   Review
2. Irritable Bowel Syndrome: A Hallmark of Psychological Distress in Women?Life (Basel, Switzerland) · 2025
   Review
3. Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.AMB Express · 2024
   Article
4. Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options.Microorganisms · 2024
   Review
5. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment.World journal of gastroenterology · 2023
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as